Teriflunomide Inhibits Clinical Demyelinating Event in Patie

Teriflunomide treatment incurred an unadjusted risk reduction of 63% and an adjusted risk reduction of 72% in inhibiting a first clinical demyelinating event in patients with multiple sclerosis (MS).

Related Keywords

, Radiologically Isolated Syndrome , Multicenter Randomized Double Blinded Assessment , First Attack , Autoimmune , Ms , Multiple Sclerosis , Teriflunomide , Clinical Demyelinating Event , Risk Reduction , Iris ,